Aligos Therapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 6, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Unregistered sales of equity securities
In May 2024, an investor exercised a Pre-Funded Warrant to purchase an aggregate of 1,115,000 shares of Common stock for an aggregate purchase price of $111.50 and was issued 1,115,000 shares of Common Stock.
In April 2024, an investor exercised a Pre-Funded Warrant to purchase an aggregate of 2,441,406 shares of Common stock for an aggregate purchase price of $244.14 and was issued 2,441,406 shares of Common Stock.
Use of proceeds
None.
Issuer purchasers of equity securities
None.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.